Adaptimmune

Adaptimmune and TCR2 Agree Merger

Clinical stage biotechs Adaptimmune and TCR2 Therapeutics have agreed to merge, forming what they said would be a “preeminent cell therapy company focused on creating solid tumors” with projected sales of about $27 billion by 2026.

Adaptimmune Strengthens Management Team with Key Executive Hires

Adaptimmune in Cancer Collaboration With GlaxoSmithKline